IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer

Cancer Letters

Volumn 352, Issue 2, 2014, Pages 214-219

  Bruchim, Ilan ^a   Sarfstein, Rive ^b   Reiss, Ari ^b   Flescher, Eliezer ^b   Werner, Haim ^b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Endometrial carcinoma; IGF1 receptor (IGF1R); Insulin like growth factor 1 (IGF1); Methyl jasmonate; NVP AEW541; Uterine serous carcinoma

Indexed keywords

JASMONIC ACID METHYL ESTER; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NVP AEW 541; SOMATOMEDIN C RECEPTOR;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CANCER; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ENDOMETRIAL CARCINOMA; IGF1 RECEPTOR (IGF1R); INSULIN-LIKE GROWTH FACTOR-1 (IGF1); METHYL JASMONATE; NVP-AEW541; UTERINE SEROUS CARCINOMA;

ACETATES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOPENTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIAL NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; OXYLIPINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; PYRROLES; RECEPTOR, IGF TYPE 1; TIME FACTORS;

EID: 84906058215     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.06.013     Document Type: Article

References (24)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. J. Clin. 2005, 55:74-108.
2. Hamilton C.A., Cheung M.K., Osann K., Chen L., Teng N.N., Longacre T.A., Powell M.A., Hendrickson M.R., Kapp D.S., Chan J.K. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br. J. Cancer 2006, 94:642-646.
3. Gunter M.J., Hoover D.R., Yu H., Wassertheil-Smoller S., Manson J.E., Li J., Harris T.G., Rohan T.E., Xue X., Ho G.Y., Einstein M.H., Kaplan R.C., Burk R.D., Wylie-Rosett J., Pollak M.N., Anderson G., Howard B.V., Strickler H.D. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol. Biomarkers Prev. 2008, 17:921-929.
4. Attias-Geva Z., Bentov I., Ludwig D.L., Fishman A., Bruchim I., Werner H. Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells. Eur. J. Cancer 2011, 47:1717-1726.
5. Attias-Geva Z., Bentov I., Fishman A., Werner H., Bruchim I. Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines. Gynecol. Oncol. 2011, 121:383-389.
6. Yeruva L., Elegbede J.A., Carper S.W. Methyl jasmonate decreases membrane fluidity and induces apoptosis through tumor necrosis factor receptor 1 in breast cancer cells. Anti-Cancer Drugs 2008, 19:766-776.
7. Cohen S., Flescher E. Methyl jasmonate: a plant stress hormone as an anti-cancer drug. Phytochemistry 2009, 70:1600-1609.
8. Fingrut O., Flescher E. Plant stress hormones suppress the proliferation and induce apoptosis in human cancer cells. Leukemia 2002, 16:608-616.
9. Kniazhanski T., Jackman A., Heyfets A., Gonen P., Flescher E., Sherman L. Methyl jasmonate induces cell death with mixed characteristics of apoptosis and necrosis in cervical cancer cells. Cancer Lett. 2008, 271:34-46.
10. Sarfstein R., Friedman Y., Attias-Geva Z., Fishman A., Bruchim I., Werner H. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PloS One 2013, 8:e61537.
11. Cesari I.M., Carvalho E., Figueiredo Rodrigues M., Mendonca B.D., Amoedo N.D., Rumjanek F.D. Methyl jasmonate: putative mechanisms of action on cancer cells cycle, metabolism, and apoptosis. Int. J. Cell Biol. 2014, 2014:572097.
12. Tong Q.S., Jiang G.S., Zheng L.D., Tang S.T., Cai J.B., Liu Y., Zeng F.Q., Dong J.H. Methyl jasmonate downregulates expression of proliferating cell nuclear antigen and induces apoptosis in human neuroblastoma cell lines. Anti-Cancer Drugs 2008, 19:573-581.
13. Cohen S., Bruchim I., Graiver D., Evron Z., Oron-Karni V., Pasmanik-Chor M., Eitan R., Bernheim J., Levavi H., Fishman A., Flescher E. Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2. J. Mol. Med. 2013, 91:357-368.
14. Heyfets A., Flescher E. Cooperative cytotoxicity of methyl jasmonate with anti-cancer drugs and 2-deoxy-d-glucose. Cancer Lett. 2007, 250:300-310.
15. Milrot E., Jackman A., Kniazhanski T., Gonen P., Flescher E., Sherman L. Methyl jasmonate reduces the survival of cervical cancer cells and downregulates HPV E6 and E7, and survivin. Cancer Lett. 2012, 319:31-38.
16. Russo A., Espinoza C.L., Caggia S., Garbarino J.A., Pena-Cortes H., Carvajal T.M., Cardile V. A new jasmonic acid stereoisomeric derivative induces apoptosis via reactive oxygen species in human prostate cancer cells. Cancer Lett. 2012, 326:199-205.
17. Rotem R., Fingrut O., Moskovitz J., Flescher E. The anticancer agent methyl jasmonate induces activation of stress-regulated c-Jun N-terminal kinase and p38 protein kinase in human lymphoid cells. Leukemia 2003, 17:2230-2234.
18. Ayabe T., Tsutsumi O., Sakai H., Yoshikawa H., Yano T., Kurimoto F., Taketani Y. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocrine J. 1997, 44:419-424.
19. Petridou E., Koukoulomatis P., Alexe D.M., Voulgaris Z., Spanos E., Trichopoulos D. Endometrial cancer and the IGF system: a case-control study in Greece. Oncology 2003, 64:341-345.
20. McCampbell A.S., Broaddus R.R., Loose D.S., Davies P.J. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin. Cancer Res. 2006, 12:6373-6378.
21. Hirano S., Ito N., Takahashi S., Tamaya T. Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. Eur. J. Gynaecol. Oncol. 2004, 25:187-191.
22. Pengchong H., Tao H. Expression of IGF-1R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial adenocarcinoma. Eur. J. Gynaecol. Oncol. 2011, 32:660-664.
23. Pavelic J., Radakovic B., Pavelic K. Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecol. Oncol. 2007, 105:727-735.
24. Elia U., Flescher E. PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate toward sarcoma cells. Neoplasia 2008, 10:1303-1313.